Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for Orgran returned no results
Showing 301 to 315 of 318 results for organ

  1. Fertility clinics must end unproven treatments that don't help couples have babies

    Fertility clinics should not offer unproven treatments that do not help people have babies, our independent committee has recommended in draft guidance.

  2. Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer (HTG315)

    Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in people having breast cancer surgery.

  3. Point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast (HTG530)

    Evidence-based recommendations on point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast. The tests are ABL800 FLEX, i-STAT Alinity and StatSensor, ABL90 FLEX PLUS, Dri chem NX500, epoc Blood Analysis System, and Piccolo Xpress.

  4. Sapropterin for treating hyperphenylalaninaemia in phenylketonuria (TA729)

    Evidence-based recommendations on sapropterin for treating hyperphenylalaninaemia in phenylketonuria.

  5. ImmunoCAP ISAC 112 for multiplex allergen testing (HTG413)

    Evidence-based recommendations on multiplex allergen testing, using ImmunoCAP ISAC 112 in people with allergy that is difficult to diagnose.

  6. Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (HTG360)

    Evidence-based recommendations on the My5-FU assay for measuring levels of 5-flurouracil (5-FU) in patients having chemotherapy, to help guide changes to the dose of 5-FU.

  7. Patient decision aids

    urinary incontinence or pelvic organ prolapse Treating complications from mesh used for stress urinary incontinence or pelvic...

  8. First licensed treatment for ultra-rare immune disorder recommended

    Leniolisib is the first ever treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) licensed for use in the NHS in England.

  9. NICE recommends life-changing gene therapy for children with ultra-rare genetic disorder

    The first and currently only gene therapy for children with an ultra-rare genetic disorder has been recommended by NICE.

  10. New treatment to increase successful kidney transplants

    A new treatment that increases the chance of a successful kidney transplant has been recommended by NICE in final draft guidance.

  11. Artificial intelligence to speed up contouring in radiotherapy treatment planning

    Nine artificial intelligence technologies can be used to help plan the treatment of those undergoing external beam radiotherapy for cancers

  12. Hundreds of thousands set to benefit from new treatment to prevent heart attacks and strokes

    NICE has published final draft guidance which recommends icosapent ethyl for reducing the risk of heart attacks and strokes in adults who have raised blood fats.

  13. Patients with rare blood disorders to receive new treatment option, says NICE

    In final guidance published today (20 May 2021), NICE has recommended ravulizumab (Ultomiris, Alexion Pharmaceuticals) as a treatment for paroxysmal nocturnal haemoglobinuria (PNH). Draft guidance published 19 May 2021 also recommends the treatment for atypical haemolytic uraemic syndrome (aHUS).

  14. NICE recommends first treatment for rare blood disorder

    People with a rare blood disorder have access to a new treatment following draft guidance from NICE.

  15. Three treatments for COVID-19 recommended in final draft guidance

    Everyone with COVID-19 at highest risk of developing severe disease will have access to clinically and cost-effective treatments.